Autopsy report · NCT04741074

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

“low recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 1 year 6 months before it stopped.
• 15 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Geisinger Clinic

Sponsor type

University, hospital or other

Conditions

CKD; Diabetic Kidney Disease; Type 2 Diabetes Mellitus in Obese; Obesity; Severe Obesity

Interventions

Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution; Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution

Participants

15

Sites

2

Countries

United States

Trials that died the same way

• Impact of Methadone on Prolonged Mechanical Ventilation in Patients on Continuous Treatment With Opioids
  “very low recruitment” (95% match in meaning)
• Study of Psychomotor Development and Attachment in Children Aged 6 to 30 Months With Oral Disorder
  “Recruitment too low” (92% match in meaning)
• Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants
  “poor recruitment” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.